Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine vs Dexmedetomidine in ESP Block for Mastectomy
NCT06252662Phase 4Recruiting
- Sponsor
- Naval Medical Center Portsmouth
- Start
- Oct 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of dexmedetomidine in postoperative pain (2 arms), sponsored by Naval Medical Center Portsmouth. Primary endpoint: Is bupivacaine with dexmedetomidine superior to liposomal bupivacaine in both density and duration? at 96 hours. Started Oct 2024; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06252662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252662.